Chloroquine was shown in 2004 to be active in vitro against SARS coronavirus but is of unproven efficacy and safety in patients infected with SARS-CoV-2. The drug’s potential benefits and risks for COVID-19 patients, without and with azithromycin, is discussed by Dr. David Juurlink, head of the Division of Clinical Pharmacology and Toxicology at Sunnybrook Health Sciences Centre in Toronto.
Latest posts by Hippocratic Post (see all)
- New AI model detects ninety percent of lymphatic cancer cases - 24th March 2024
- Breast Cancer Now creates emotive ‘Gallery of Hope’ powered by AI - 13th March 2024
- $8 million awarded to predict genetic disease risk - 13th March 2024